阿立哌唑与利培酮治疗首发精神分裂症的对照研究

A comparative study of aripiprazole and risperidone in the treatment of first-episode schizophrenia

目的比较阿立哌唑与利培酮治疗首发精神分裂症的疗效和安全性。方法将70例首发精神分裂症患者随机分为阿立哌唑组(n=35)和利培酮组(n=35)进行治疗,疗程8周。在治疗前及治疗后第1、2、4及8周末采用阳性阴性症状量表(PANSS)及不良反应量表(TESS)评定其疗效及药物不良反应。结果阿立哌唑的治疗有效率为64.7%,利培酮的治疗有效率为63.6%,两组疗效差异无显著性。两药均无严重不良反应,但阿立哌唑的肌强直、静坐不能以及泌乳、月经紊乱的发生率明显低于利培酮。结论阿立哌唑与利培酮治疗首发精神分裂症均有效,前者不良反应更少、更安全。

Objective To evaluate the efficacy and safety of aripiprazole and risperidone in the treatment of first-episode schizophrenia. Methods A total of 7 patients with first-episode schizophrenia were randomly divided into aripiprazole group and risperidone group. The treatment duration was six weeks. PANSS and TESS were used to evaluate the efficacy and side-effect respectively before treatment and on the 1st,2nd,4th and 8th weekend of after treatment. Results The effective rates of aripiprazole and risperidone were 64.7% and 63.6% respectively, which showed no significant difference. There were no severe side effect in both group, but the rate of some adverse effects including akathisia, myotonia, lactation and menstruation disorder in aripiprazole group were fewer than that in risperidone group. Conclusion Aripiprazole and risperidone are effective in the treatment of first-episode schizophrenia. Aripiprazole has few adverse effects.